Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118


Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.

Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL.

Int J Parasitol Drugs Drug Resist. 2019 Feb 26. pii: S2211-3207(18)30185-4. doi: 10.1016/j.ijpddr.2019.02.002. [Epub ahead of print]


Leishmaniasis - Authors' reply.

Burza S, Croft SL, Boelaert M.

Lancet. 2019 Mar 2;393(10174):872-873. doi: 10.1016/S0140-6736(18)33057-5. No abstract available.


Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis.

Ashwin H, Seifert K, Forrester S, Brown N, MacDonald S, James S, Lagos D, Timmis J, Mottram JC, Croft SL, Kaye PM.

Version 2. Wellcome Open Res. 2019 Jan 2 [revised 2019 Jan 1];3:135. doi: 10.12688/wellcomeopenres.14867.2. eCollection 2018.



Burza S, Croft SL, Boelaert M.

Lancet. 2018 Sep 15;392(10151):951-970. doi: 10.1016/S0140-6736(18)31204-2. Epub 2018 Aug 17. Review.


Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.

Wijnant GJ, Van Bocxlaer K, Fortes Francisco A, Yardley V, Harris A, Alavijeh M, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00631-18. doi: 10.1128/AAC.00631-18. Print 2018 Oct.


Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Alavijeh M, Silva-Pedrosa R, Antunes S, Mauricio I, Murdan S, Croft SL.

Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):223-228. doi: 10.1016/j.ijpddr.2018.04.001. Epub 2018 Apr 12.


Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles.

Van Bocxlaer K, Gaukel E, Hauser D, Park SH, Schock S, Yardley V, Randolph R, Plattner JJ, Merchant T, Croft SL, Jacobs RT, Wring SA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02419-17. doi: 10.1128/AAC.02419-17. Print 2018 May.


Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.

Voak AA, Standing JF, Sepúlveda N, Harris A, Croft SL, Seifert K.

J Antimicrob Chemother. 2018 May 1;73(5):1314-1323. doi: 10.1093/jac/dky014.


Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Harris A, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02009-17. doi: 10.1128/AAC.02009-17. Print 2018 Mar.


In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial.

Basilico N, Parapini S, Sparatore A, Romeo S, Misiano P, Vivas L, Yardley V, Croft SL, Habluetzel A, Lucantoni L, Renia L, Russell B, Suwanarusk R, Nosten F, Dondio G, Bigogno C, Jabes D, Taramelli D.

Molecules. 2017 Dec 1;22(12). pii: E2102. doi: 10.3390/molecules22122102.


Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.

Croft SL.

Parasitology. 2018 Feb;145(2):237-247. doi: 10.1017/S0031182017001664. Epub 2017 Oct 6. Review.


A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission.

Baker DA, Stewart LB, Large JM, Bowyer PW, Ansell KH, Jiménez-Díaz MB, El Bakkouri M, Birchall K, Dechering KJ, Bouloc NS, Coombs PJ, Whalley D, Harding DJ, Smiljanic-Hurley E, Wheldon MC, Walker EM, Dessens JT, Lafuente MJ, Sanz LM, Gamo FJ, Ferrer SB, Hui R, Bousema T, Angulo-Barturén I, Merritt AT, Croft SL, Gutteridge WE, Kettleborough CA, Osborne SA.

Nat Commun. 2017 Sep 5;8(1):430. doi: 10.1038/s41467-017-00572-x.


Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.

Voak AA, Harris A, Qaiser Z, Croft SL, Seifert K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00497-17. doi: 10.1128/AAC.00497-17. Print 2017 Sep.


Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis.

Wijnant GJ, Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00358-17. doi: 10.1128/AAC.00358-17. Print 2017 Aug.


Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.

Burrell-Saward H, Harris AJ, de LaFlor R, Sallam H, Alavijeh MS, Ward TH, Croft SL.

Int J Antimicrob Agents. 2017 Aug;50(2):203-209. doi: 10.1016/j.ijantimicag.2017.01.038. Epub 2017 May 25.


Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense.

Daunes S, Yardley V, Croft SL, D'Silva C.

Bioorg Med Chem. 2017 Feb 15;25(4):1329-1340. doi: 10.1016/j.bmc.2016.12.016. Epub 2016 Dec 18.


Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.

Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

J Pharm Pharmacol. 2016 Jul;68(7):862-72. doi: 10.1111/jphp.12548. Epub 2016 May 27.


A Replicative In Vitro Assay for Drug Discovery against Leishmania donovani.

Tegazzini D, Díaz R, Aguilar F, Peña I, Presa JL, Yardley V, Martin JJ, Coteron JM, Croft SL, Cantizani J.

Antimicrob Agents Chemother. 2016 May 23;60(6):3524-32. doi: 10.1128/AAC.01781-15. Print 2016 Jun.


Drug permeation and barrier damage in Leishmania-infected mouse skin.

Van Bocxlaer K, Yardley V, Murdan S, Croft SL.

J Antimicrob Chemother. 2016 Jun;71(6):1578-85. doi: 10.1093/jac/dkw012. Epub 2016 Feb 21.


Supplemental Content

Loading ...
Support Center